BPC-157

What it is

BPC-157 (Body Protective Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of a larger gastric protein originally isolated from human gastric juice in the 1990s by Predrag Sikiric and colleagues at the University of Zagreb. The name reflects the protective role its discoverers hypothesized for it. Its full peptide sequence is GEPPPGKPADDAGLV.

BPC-157 is not FDA-approved for any use in the United States. Its research literature is mainly preclinical, with more than 200 published animal studies across a range of injury models. The WADA (World Anti-Doping Agency) has placed BPC-157 on its prohibited list for athletes since 2022.

In laboratory testing, BPC-157 has been reported to remain stable in human gastric juice for over 24 hours, which is unusual for a peptide.

Mechanism of action

Proposed mechanisms come from laboratory and animal research. Reported effects in preclinical models include:

• Angiogenesis: in animal models, BPC-157 has been reported to increase expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR2, and to be associated with new blood vessel formation around injured tissue.
• Nitric oxide system modulation: animal studies have reported interactions with the nitric oxide signaling system, including reversal of some effects of NOS blockade.
• Growth factor expression: in laboratory (cell) studies, BPC-157 has been reported to increase expression of growth hormone receptor on tendon fibroblasts.
• Gastric mucosal effects: the original observation behind the peptide’s isolation. In animal studies, BPC-157 was associated with reduced gastric mucosal damage from NSAIDs, alcohol, and acid.
• Dopaminergic and serotonergic effects: modulation of these neurotransmitter systems has been reported in animal models, including in models of CNS injury.

The range of reported mechanisms has also raised skepticism — peptides with narrow receptor specificity are usually easier to characterize than ones reported to do many different things.

Research findings

The gap between preclinical and human evidence is BPC-157’s defining feature.

Preclinical evidence: in animal studies, BPC-157 has been reported to be associated with faster healing and greater tensile strength of repaired tissue, reduced inflammation, and reduced tissue damage in models of tendon and ligament injury, gastric ulceration, inflammatory bowel disease, traumatic brain injury, fracture, diabetic wounds, and ischemia-reperfusion injury. Much of this work comes from the Sikiric laboratory and collaborating groups, with some studies by independent investigators.

Human evidence: no large randomized controlled trials in humans exist. A small Phase I study examined basic pharmacokinetics. Other human reports are limited to small case series, which cannot establish effectiveness or safety.

Why the gap exists: BPC-157 is not patent-protected as a novel composition (it’s a fragment of a naturally occurring protein), which reduces pharmaceutical industry incentive to fund the large trials needed for FDA approval. Well-controlled human trials establishing its effectiveness and safety are lacking.

Side effects and contraindications

The safety of BPC-157 in humans has not been established in well-controlled clinical trials, and its long-term effects are unknown. Products sold outside regulated channels (for example, as “research peptides”) may vary in purity, dose, and sterility.

Theoretical concerns:

• Angiogenesis and malignancy: any agent reported to promote new blood vessel formation could theoretically support tumor vascularization, which is a particular concern for people with active or recent cancer or undiagnosed lumps.
• Pregnancy and breastfeeding: no safety data exist for these populations.

What we don’t yet know

The most fundamental gap is the absence of large human RCTs evaluating any specific condition. Human safety, including long-term safety, has not been characterized. The basis for the tissue-specific effects reported in animal studies is not explained. BPC-157 remains an investigational compound whose effects in people have not been established.